Hormonal
Tirzepatide treatment (10 mg or 15 mg once weekly for 72 weeks) significantly improves self-reported health-related quality of life (HRQoL) in adults with obesity or overweight and type 2 diabetes, specifically in physical functioning, bodily pain, general health, vitality, and social functioning.
If you have type 2 diabetes and are overweight or obese, treatment with tirzepatide (Mounjaro/Zepbound) can significantly improve your daily quality of life. This includes feeling less pain, having more energy, and being more socially active. The improvements are seen in both physical and mental well-being, and they are greater for those who lose more weight. Talk to your doctor about whether this once-weekly injection is right for you, especially if you are struggling with physical limitations due to your weight.
At week 72, tirzepatide treatment was associated with significantly larger improvements than placebo in the SF-36v2 Physical Component Summary score, SF-36v2 physical functioning, bodily pain, general health, vitality, and social functioning domain scores, all IWQOL-Lite-CT scores, and EQ VAS score.
Why this rating
The study is a phase 3, randomized, double-blind, multicenter clinical trial, which is the gold standard for clinical evidence.
Source
Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial
Theresa Hunter et al. · Diabetes Therapy · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →